retreatment

QLT Announces Second Quarter Results for 2009

...ose of the study is to determine if Visudyne combined with Lucentis reduces retreatment rates compared with Lucentis monotherapy, while maintaining similar vision ...aluated against Lucentis monotherapy. The overall results showed that fewer retreatment visits were required with the combination therapies than with Lucentis mono...

Good news for some hard-to-treat hepatitis C patients

... dose of consensus interferon and ribavirin. "This study shows that select patients who have failed to respond to prior therapy are candidates for retreatment with consensus interferon and ribavirin," Bacon said. ...

QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy

...terval of at least four months duration after Month 2. Median time to first retreatment after month 2 was extended by ~1 month in the combination group (month 6) v... VA, anatomical changes and safety at every monthly visit, and the need for retreatment was assessed at monthly visits from Month 3 to Month 11. Re-treatment was b...

QLT announces positive results from the evaluation of Visudyne(R) combination therapy

...termine if Visudyne combined with Lucentis reduces retreatment rates compared with Lucentis monotherapy, while ma...monotherapy. The overall results showed that fewer retreatment visits were required with the combination therapie...oup demonstrated the best results, with the fewest retreatment visits and mean VA improvement most similar to Luc...

New treatment option for patients with chronic hepatitis C

... respond to treatment with peg-IFN and RBV can be successfully retreated with daily CIFN and RBV," the authors conclude. "The greatest SVR rate during retreatment in the present study was observed in F0-F3 patients who had a partial virologic response during their prior course of treatment." ...

Schering-Plough Reports Financial Results for 2009 First Quarter

... TEMODAL Capsules. (Announced March 5) Received FDA approval for expanded labeling for PEGINTRON and REBETOL combination therapy allowing for retreatment of chronic hepatitis C patients 3 years of age and older with compensated liver disease who have failed prior therapy. (Announced March 11) R...

Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions

...Nonanimal-Stabilized Hyaluronic Acid 100,000 Gel Particles/mL Filler on Two retreatment Schedules: Results up to 18 months on Two retreatment Schedules. Narins et. al. Dermatologic Surgery 2008;34:S2-S8. (4) U.S. FDA...

Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma

...were available for 985 patients. Rituximab maintenance therapy was associated with a 40% improvement in overall survival relative to observation or retreatment with rituximab at relapse. The improvement in overall survival was statistically significant for patients with relapsed or refractory lymphoma, but no...

QLT announces interim results of radical study evaluating Visudyne combination therapy

...udy is to determine if combination therapy reduces retreatment rates compared with Lucentis monotherapy while mai...etters; Group 4: 4.4 letters). Although cumulative retreatment rates were lower in all combination groups compare...follow up is needed to better compare the elective retreatment rates in each group. "Determining if Visudyne ...

Estrogen pills can benefit women with metastatic breast cancer

...n dependent tumors and the cycle starts over." Ellis plans to continue to follow metastatic breast cancer patients to quantify the response rate to retreatment with aromatase inhibitors when estrogen therapy stops working. ...

retreatment in Medical Technology

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

...nal control. Of these, 454 patients were from the retreatment study portion of the EPIC3 program and 172 were di...ng characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonres.... Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination re...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

...Patients with the following characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonresponse, previous pegylated...th inhibition were common. Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination regimen reported adverse re...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

...ve patients. Patients less likely to benefit from retreatment after failing a course of therapy include those wi...ine those patient groups most likely to respond to retreatment as well as those unlikely to respond. Overall, pr...cians can identify which patients may be right for retreatment with PEGINTRON combination therapy and may have th...

Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection

...r-blinded study that assessed the safety and effectiveness of two different retreatment schedules, 4.5 months or 9 months, after initial treatment of nasolabial fo... Correction with Restylane (R) lasted for 18 months, regardless of retreatment schedule At 18 months, patients still had a 1.7 grade improvement i...

Genmab Announces Upcoming Ofatumumab Studies

... Front Line CLL, NHL and CLL retreatment and Japanese Development Studies ...tment of front line CLL. Phase II CLL ofatumumab retreatment and maintenance treatment study This study will examine the retreatment and maintenance treatment of refractory CLL patien...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

...Data Presentations at DDW PEGINTRON Results from the EPIC3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the retreatment of Previous Interferon/Ribavirin Non-Responders (NR). Poynard, T. et al. Poster S1000, Abstract No. 442673, Sunday, May 18, 8:00 a.m. - 5:00 p.m., Sai...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

...tained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): final resul... combination with ribavirin in initial therapy, the optimal approach to the retreatment of patients with chronic HCV for whom initial treatment was not effective, ...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

...ill be presented from 23 studies of VELCADE based therapies for the treatment of relapsed MM. These data, including settings where VELCADE is used for retreatment and in patients with renal impairment, support the importance of adding VELCADE in combination with numerous emerging and established agents. Non-Ho...

Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis

...ent. Ongoing patient evaluations showed maintenance of ACR responses with repeated single doses of TRU-015 at six-month intervals through at least two retreatment courses. Total serum IgG levels remained within normal limits. In addition, subjects treated with three or more courses of therapy experienced persist...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

...r of the SPIRIT III clinical trial. "In SPIRIT III, the risk for patients on the important clinical endpoint of MACE -- cardiac death, heart attack or retreatment in the diseased artery area -- was approximately 43 percent lower with XIENCE V than TAXUS at 1 year. A reduction in MACE with Xience V compared to TA...

retreatment in Medical Products

Seibel II IntraLase Flap Lifter & Retreatment Spatula, Titanium

Description: Unique In-Line Footplates Are Turned 90 Degrees To Allow Full Visualization Of The Diamond Blade While Incising Tissue. Special Mirror-Polished Double Footplate Construction Insures Precise Blade Depth Penetration. Pre-Set Blade Extension Settings Of 0.5mm, 0.55mm, 0.6mm, Including Ful...
Company:Rhein Medical, Inc.

LASIK Retreatment Forceps

Description: LASIK Retreatment Forceps - Also available in Titanium...
Company:Khosla Medical & Surgical, Inc.

Rousseau IntraLASIK Flap Spreader

Description:...e With The Smooth Lifting Of The Flap. Designed To Be Used Specifically For Lamellar Flaps Created With The IntraLase TMFS Laser System, And For retreatment Flaps Originally Created By Mechanical Microkeratomes. Optimal Results Are Experienced With Flaps Measuring 100+ Microns....
Company:Rhein Medical, Inc.

Probst Lasik Spatula

Description:... Lasik spatula useful for protecting a previous flap for retreatment to lift and smooth the corneal flap....
Company:Bausch & Lomb Storz

retreatment in Biological News

Gene therapy may protect normal tissues during radiation retreatment for lung cancer

The ice ages made massive changes to the Earth's landscape The ice ages made massive changes to the Earth's landscape. But what was happening below the ice in the oceans? Research by marine scientists reveals that it was a time of mass destruction as whole communities of animals were wiped out...

JCI table of contents: Aug. 16, 2007

...linical Investigation, Charles Sawyers and colleagues show that 2 of 12 patients whose cancer had returned after treatment with dasatinib responded to retreatment with imatinib. Analysis of the BCR-ABL proteins from these patients revealed that their BCR-ABL had only the dasatinib-resistance mutation. By contras...

Novel therapy combinations gain ground in treating hepatitis

...akthroughs and relief for these patients." Valopicitabine (NM283), Alone or with Peg-Interferon, Compared to Peg Interferon/Ribavirin (pegIFN/RBV) retreatment in Hepatitis C Patients with Prior Non-Response to PegIFN/RBV: Week 24 Results [Abstract 4] More than half of currently treated hepatitis patients...

retreatment in Biological Technology

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

...d interferon (PEG-IFN) plus ribavirin (RBV). "The retreatment of PEG-IFN/RBV nonresponders with INFERGEN and RBV is safe and efficacious and can be considered a retreatment strategy for patients failing previous therapy wit...nts who failed initial treatment with PEG-IFN/RBV, retreatment with INFERGEN in combination with RBV yielded SVR ...

Leading Refractive Eye Surgery Experts from Trusted LASIK Surgeons Directory Educate Peers at ASCRS Annual Meeting

... at UT Southwestern Medical Center in Dallas , authored or co-authored over 14 presentations at the ASCRS meeting. In "Wavefront-Guided Ablation retreatment in Myopic Eyes" (E.M. Mohamed; O. Muftuoglu; R. Bowman; D. Cavanagh; V. Mootha; J.P. McCulley), the researchers concluded that that using Wavefro...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

... first-line docetaxel therapy, but subsequently have progression of disease, including prostate cancer-related pain, and are able to receive docetaxel retreatment as second-line chemotherapy. Patients will be randomized to receive treatment with either OGX-011 and docetaxel/prednisone or docetaxel/prednisone alo...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... combination with either mitoxantrone or docetaxel retreatment as second-line chemotherapy as compared to... patients receiving OGX-011 plus docetaxel retreatment was 15.8 months, whereas the median survival durat...s to be treated with OGX-011 and docetaxel retreatment as second-line chemotherapy. The median su...

Genmab Announces Results for the First Nine Months of 2008

...CLL front line chlorambucil combination study. 2) Phase II CLL ofatumumab retreatment and maintenance treatment study for patients who have participated in the ongoing Phase III CLL study. 3) Phase II NHL ofatumumab retreatment and maintenance study for patients who have participated in the ongoing...

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today

...cal trial evaluating OGX-011 in combination with second-line chemotherapy in patients with hormone refractory prostate cancer has shown that retreatment with docetaxel in combination with OGX-011 may reverse docetaxel resistance and improve patient survival. In July 2008, OncoGenex Technologi...

OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011

...2 studies of OGX-011 in combination with docetaxel retreatment have indicated that OGX-011 may help restore tumor...ntrone plus OGX-011 and 20 patients with docetaxel retreatment plus OGX-011. While follow up on surviving patient... OGX-011 group and 14.7 months in the docetaxel retreatment plus OGX-011 group. These data compare favorabl...

Sonus Pharmaceuticals and OncoGenex Technologies to Merge

... trial evaluating OGX-011 in combination with second-line chemotherapy in patients with hormone refractory prostate cancer has shown that retreatment with docetaxel in combination with OGX-011 may reverse docetaxel resistance and improve survival. OGX-011 is planned to enter randomized cli...

OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer

... the effect of OGX-011 in combination with either mitoxantrone or docetaxel retreatment as second-line chemotherapy. Phase 3 studies are planned utilizing chemothe...is also the primary investigator in the study. "The data also suggests that retreatment with docetaxel when combined with OGX-011 may reverse chemotherapy resistan...